Literature DB >> 11502872

Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor.

B Goodwin1, L B Moore, C M Stoltz, D D McKee, S A Kliewer.   

Abstract

Cytochromes P450 (P450s) are involved in the oxidative metabolism of a plethora of structurally unrelated compounds, including therapeutic drugs. Two orphan members of the nuclear receptor superfamily, the pregnane X receptor (PXR; NR1I2) and constitutive androstane receptor (CAR; NR1I3) have been implicated in this phenomenon. In the present study, we examined the transcriptional regulation of the human CYP2B6 gene. In primary cultures of human hepatocytes, CYP2B6 was highly inducible by a number of compounds known to be human PXR ligands, including rifampicin and hyperforin. PXR was shown to be capable of activating the phenobarbital-responsive enhancer module (PBREM) region of the CYP2B6 gene, a 51-base-pair enhancer element that mediates induction of CYP2B6 expression by CAR. The two nuclear receptor-binding motifs within the PBREM effectively bound PXR as a heterodimer with the 9-cis retinoic acid receptor alpha (NR2B1). Taken together, these observations demonstrate that the CYP2B6 gene is directly regulated by PXR and further establish this receptor as a key regulator of drug-metabolizing P450s.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11502872

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  76 in total

Review 1.  A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha, and LXRbeta.

Authors:  Sean Ekins; Leonid Mirny; Erin G Schuetz
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

Review 2.  Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR.

Authors:  Antonia H Tolson; Hongbing Wang
Journal:  Adv Drug Deliv Rev       Date:  2010-08-17       Impact factor: 15.470

3.  Bioactivation of chlorpyrifos by CYP2B6 variants.

Authors:  Alice L Crane; Kathrin Klein; James R Olson
Journal:  Xenobiotica       Date:  2012-07-10       Impact factor: 1.908

4.  PharmGKB summary: very important pharmacogene information for CYP2B6.

Authors:  Caroline F Thorn; Jatinder K Lamba; Vishal Lamba; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2010-08       Impact factor: 2.089

Review 5.  Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism.

Authors:  Timothy S Tracy; Amarjit S Chaudhry; Bhagwat Prasad; Kenneth E Thummel; Erin G Schuetz; Xiao-Bo Zhong; Yun-Chen Tien; Hyunyoung Jeong; Xian Pan; Laura M Shireman; Jessica Tay-Sontheimer; Yvonne S Lin
Journal:  Drug Metab Dispos       Date:  2015-12-17       Impact factor: 3.922

6.  Genetic polymorphisms of pharmacogenomic VIP variants in the lhoba population of southwest China.

Authors:  Yongjun He; Hua Yang; Tingting Geng; Tian Feng; Dongya Yuan; Longli Kang; Manling Luo; Tianbo Jin
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

7.  Genome-wide analysis of human constitutive androstane receptor (CAR) transcriptome in wild-type and CAR-knockout HepaRG cells.

Authors:  Daochuan Li; Bryan Mackowiak; Timothy G Brayman; Michael Mitchell; Lei Zhang; Shiew-Mei Huang; Hongbing Wang
Journal:  Biochem Pharmacol       Date:  2015-08-12       Impact factor: 5.858

8.  Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein.

Authors:  Anna M Lee; Sharon Miksys; Rachel F Tyndale
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

Review 9.  Post-translational and post-transcriptional modifications of pregnane X receptor (PXR) in regulation of the cytochrome P450 superfamily.

Authors:  Tomas Smutny; Sridhar Mani; Petr Pavek
Journal:  Curr Drug Metab       Date:  2013-12       Impact factor: 3.731

Review 10.  Alterations of chemotherapeutic pharmacokinetic profiles by drug-drug interactions.

Authors:  Sridhar Mani; Mohammed Ghalib; Imran Chaudhary; Sanjay Goel
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-02       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.